Milestones

1. Relevance of developing environmentally sustainable policies in digestive endoscopy.

2. Systematisation of immune system alterations in patients with cirrhosis. "Albillos A, Martin-Mateos R, Van der Merwe S, Wiest R, Jalan R, Álvarez-Mon M. Cirrhosis-associated immune dysfunction. Nat Rev Gastroenterol Hepatol. 2022; 19(2):112-134. doi: 10.1038/s41575-021-00520-7. PMID: 34703031."

3. Superiority of echoendoscopy-guided gastroenterostomy versus duodenal prosthesis in the treatment of tumoral pyloric obstruction. "Sánchez-Aldehuelo R, Subtil Iñigo JC, Martínez Moreno B, Gornals J, Guarner-Argente C, Repiso Ortega A, Peralta Herce S, Aparicio JR, Rodríguez de Santiago E, Bazaga S, Juzgado D, González-Panizo F, Albillos A, Vázquez-Sequeiros E. EUS-guided gastroenterostomy versus duodenal self-expandable metal stent for malignant gastric outlet obstruction: results from a nationwide multicenter retrospective study (with video). Gastrointest Endosc. 2022; 96(6):1012-1020.e3. doi: 10.1016/j.gie.2022.07.018. PMID: 35870508."

4. Identification of the limitations to the use of beta-blockers in the patient with cirrhosis and ascites". Téllez L, Albillos A. "Non-selective beta-blockers in patients with ascites: The complex interplay among the liver, kidney and heart. Liver Int. 2022; 42(4):749-761. doi: 10.1111/liv.15166. PMID: 35051310."

5. Utility of vedolizumab and ustekinumab in the treatment of joint manifestations of inflammatory bowel disease. "De Galan C, Truyens M, Peeters H, Mesonero Gismero F, Elorza A, Torres P, Vandermeulen L, Amezaga AJ, Ferreiro-Iglesias R, Holvoet T, Zabana Y, Reverter LP, Gonzales GB, Geldof J, Varkas G, De Vos M, Lobatón T. The Impact of Vedolizumab and Ustekinumab on Articular Extra-Intestinal Manifestations in Inflammatory Bowel Disease Patients: A Real-Life Multicentre Cohort Study. J Crohns Colitis. 2022; 16(11):1676-1686. doi: 10.1093/ecco-jcc/jjac058. PMID: 35442433."